Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

        Print
| Source: Vitrolife AB
The Election Committee of Vitrolife, which was appointed in accordance with the
resolution of the Annual General Meeting on April 29, 2013, consists of:

Patrik Tigerschiöld, representing Bure Equity AB
Thomas Olausson
Martin Lewin, representing Eccenovo AB
Carsten Browall, Chairman of the Board

The Election Committee proposes the following to the Annual General Meeting of
Vitrolife that will take place on Monday May 5, 2014:

  ·
that the Chairman of the meeting shall be Carsten Browall, Chairman of the Board
of Vitrolife.

  ·
that the members of the Board shall be six in number (unchanged).

  ·
that the Board remuneration shall be SEK 1,100,000, of which SEK 330,000 to the
Chairman of the Board, SEK 150,000 to each of the other members of the Board and
SEK 30,000 to the Chairman of the Audit Committee. The proposal equals an
increase of SEK 210.000 of the total amount compared to the previous year.

  ·
re-election of the Board members Fredrik Mattsson, Maris Hartmanis, Tord Lendau,
Barbro Fridén, Carsten Browall and Pia Marions.

  ·
re-election of Carsten Browall as Chairman of the Board.

  ·
election of Deloitte AB, with authorized public accountants Jan Nilsson (head
auditor) and Fredrik Jonsson, as auditor for a term of 3 years.

  ·
that a new Election Committee be set up for the Annual General Meeting of 2015.
It is proposed that the Election Committee is appointed in the same way as
previously, whereby the Chairman of the Board contacts the three largest
registered shareholders or otherwise known owners at the end of the third
quarter of 2014 and asks them to appoint one member each. The three members who
are appointed and the Chairman of the Board constitute the Election Committee.
The Election Committee appoints a Chairman internally.
Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Carsten Browall, Board member, phone 46 70 255 65 32

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
31, 2014 at 11.00 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/